Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	4882
Country	Spain

Received	2013-07-30 10:14
Peer-Review Started	2013-07-30 21:41
To Make the First Decision	2013-08-08 11:19
Return for Revision	2013-08-20 20:29
Revised
Second Decision	2013-12-10 16:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-12-11 10:06
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-12-13 23:50
Typeset the Manuscript	2014-01-27 15:27
Publish the Manuscript Online	2014-01-27 17:26

ISSN	2150-5349 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Aspirin, cyclooxygenase inhibition and colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Carlos Sostres, Carla Jerusalen Gargallo and Angel Lanas
Funding Agency and Grant Number	Funding Agency Grant Number FIS P108/1301 AstraZeneca, Pfizer and Bayer (to Dr. Lanas A)
Corresponding Author	Angel Lanas, MD, DSc, Clinical Chief, Professor, Department of Digestive Diseases, University Hospital Lozano Blesa, c/Domingo Miral s/n, 50009 Zaragoza, Spain. alanas@unizar.es
Key Words	Aspirin; Colorectal cancer; Cyclooxygenase inhibition; Mechanisms; Risk; Benefits
Core Tip	Colorectal cancer (CRC) is a major cause of morbidity and mortality worldwide. Currently, CRC screening programs are not widely available and need to be improved. New prevention strategies are therefore necessary. Daily low-dose aspirin, as given for the prevention of cardiovascular disease events, has demonstrated benefits in clinical and basic studies in terms of preventing adenoma recurrence and decreasing the incidence of CRC and attributable mortality. These findings indicate that the antiplatelet action of aspirin plays a central role in its antitumor effect. Cyclooxygenase-dependent and independent mechanisms have been suggested to explain this effect. Extensive translational medical research is mandatory for future progress in CRC prevention.
Publish Date	2014-01-27 17:26
Citation	Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Phar-macol Ther 2014; 5(1): 40-49
URL	http://www.wjgnet.com/2150-5349/full/v5/i1/40.htm
DOI	http://dx.doi.org/10.4292/wjgpt.v5.i1.40

Full Article (PDF)	WJGPT-5-40.pdf
Full Article (Word)	WJGPT-5-40.doc
Manuscript File	4882-Review.doc
Answering Reviewers	4882-Answering reviewers.pdf
Copyright License Agreement	4882-Copyright assignment.pdf
Peer-review Report	4882-Peer reviewer(s).pdf
Scientific Editor Work List	4882-Scientific editor work list.doc